According to FutureWise analysis the market for biologics safety testing in 2023 was US$ 4.08 billion, and is expected to reach US$ 11.18 billion by 2031 at a CAGR of 13.4%. Biologics are a category of therapeutic products sourced from living organisms. This includes a variety of treatments such as proteins, monoclonal antibodies, vaccines, as well as cell and gene therapies. Unlike...